You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR LEVETIRACETAM IN SODIUM CHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LEVETIRACETAM IN SODIUM CHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00015769 ↗ Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness Completed National Institute of Mental Health (NIMH) Phase 2 2001-04-01 This study will explore the possible effectiveness of levetiracetam in patients with bipolar illness who have not responded adequately to standard treatments. Levetiracetam was recently approved to treat seizures. Other drugs in the same class as levetiracetam, including carbamazepine and valproate, are widely recognized as substitute medications for lithium or are used as an adjunct to it, and other anticonvulsants have also shown promise in improving bipolar symptoms. Patients with bipolar illness whose manic, depressed or unstable moods are not adequately controlled by their current treatment and who have not responded previously to two standard treatments (i.e., lithium, valproate, carbamazepine or neuroleptics) may be eligible for this study. Participants will take levetiracetam starting at 500 mg daily. If this dose is well tolerated, it will be increased to 500 mg twice a day. Every 3 days, doses may be increased until the target dose of 3000 mg/day is reached. Higher doses, not to exceed 4000 mg/day, may be tried in patients who do not respond fully to the lower doses. Patients and observers will use standard ratings to evaluate the patients' response to therapy during the 8-week study. If, after 8 weeks, the results appear promising, patients may continue treatment for an additional 6 months to evaluate longer-term effects.
NCT00068770 ↗ Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated National Cancer Institute (NCI) Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
NCT00068770 ↗ Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT Terminated Sidney Kimmel Comprehensive Cancer Center Phase 2 2003-10-01 RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LEVETIRACETAM IN SODIUM CHLORIDE

Condition Name

Condition Name for LEVETIRACETAM IN SODIUM CHLORIDE
Intervention Trials
Epilepsy 50
Seizures 17
Epilepsy, Partial 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LEVETIRACETAM IN SODIUM CHLORIDE
Intervention Trials
Epilepsy 82
Seizures 74
Epilepsies, Partial 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LEVETIRACETAM IN SODIUM CHLORIDE

Trials by Country

Trials by Country for LEVETIRACETAM IN SODIUM CHLORIDE
Location Trials
United States 328
Japan 49
Germany 30
France 24
Italy 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LEVETIRACETAM IN SODIUM CHLORIDE
Location Trials
Ohio 21
Maryland 20
California 19
Massachusetts 18
Texas 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LEVETIRACETAM IN SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for LEVETIRACETAM IN SODIUM CHLORIDE
Clinical Trial Phase Trials
Phase 4 47
Phase 3 54
Phase 2/Phase 3 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LEVETIRACETAM IN SODIUM CHLORIDE
Clinical Trial Phase Trials
Completed 138
Recruiting 23
Terminated 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LEVETIRACETAM IN SODIUM CHLORIDE

Sponsor Name

Sponsor Name for LEVETIRACETAM IN SODIUM CHLORIDE
Sponsor Trials
UCB Pharma 69
UCB Japan Co. Ltd. 11
National Institute of Neurological Disorders and Stroke (NINDS) 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LEVETIRACETAM IN SODIUM CHLORIDE
Sponsor Trials
Other 246
Industry 130
NIH 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.